Business
Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that new preclinical data for its lead antibody radioconjugate program, ATNM‑400, will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) taking place December 10‑14, 2025 in San Antonio, Texas.
About this update from Actinium Pharmaceuticals, Inc. (delaware)
[{"type":"text","content":"- New preclinical data to show anti-tumor activity of ATNM-400 in hormone-resistant and HER2-resistant breast cancer, addressing the need for new treatment options beyond tamoxifen and trastuzumab","length":201,"tagName":"p","attribs":{}},{"type":"text","content":"- ATNM-400 demonstrates efficacy across prostate cancer, non-small cell lung cancer (NSCLC), and breast cancer - three of the largest oncology indications - with potential as monotherapy, in combination, or as an alternative therapy","length":232,"tagName":"p","attribs":{}},{"type":"text","content":"NEW YORK, Nov. 4, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a leader in the development of differentiated targeted radiotherapies, announced today that new preclinical data for its lead antibody radioconjugate program, ATNM‑400, will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) taking place December 10‑14, 2025 in San Antonio, Texas.","length":442,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Actinium Pharmaceuticals, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Actinium Pharmaceuticals, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":97,"url":"https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/yUttGl4ecQ0sM9T7v.HK4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/eb2937f11974a18d93e636c38ac22747","width":400,"height":97}},"href":"https://mma.prnewswire.com/media/730678/Actinium_Pharmaceuticals_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Title: Anti‑tumor activity of ATNM‑400, a first‑in‑class Actinium‑225 antibody radioconjugate, in tamoxifen and trastuzumab resistant breast cancer models","length":154,"tagName":"p"},{"type":"text","content":"Abstract Number: 2069Presentation Number: PS4‑04‑26Date/Time: Thursday, December 11, 2025, 5:00 PM–6:30 PM CTSession: Poster Session 4","length":137,"tagName":"p"},{"type":"text","content":"The ATNM-400 data presentation at SABCS follows prostate cancer data presentations at the American Association for Cancer Research (AACR) annual meeting and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annu...